IP Library Granted Patent US 8,175,711
Granted Patent B2
US 8,175,711 · App. 11/368,553 · Granted May 8, 2012

Methods for treating a condition or disease associated with cardio-renal function

Assignee: Ardian, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,175,711
App. No.
11/368,553
Granted
May 8, 2012
Kind
B2
Abstract

Methods and apparatus are provided for treating congestive heart failure, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.

Claims (39)

1. A method for treating a human patient with diagnosed hypertension, the method comprising:

positioning a nerve modulation device in a vicinity of post-ganglionic neural fibers that innervate a kidney of the patient; and

reducing neural communication to and from the kidney with the nerve modulation device,

wherein reducing neural communication to and from the kidney significantly improves a measureable physiological parameter associated with the hypertension of the patient,

wherein the kidney continues to secrete renin in the patient after reducing neural communication with the nerve modulation device.

2. The method of claim 1 wherein positioning a nerve modulation device in a vicinity of post-ganglionic neural fibers comprises positioning the nerve modulation device within a blood vessel of the patient.

3. The method of claim 2 wherein positioning the nerve modulation device within a blood vessel further comprises positioning the nerve modulation device within a renal blood vessel of the patient.

4. The method of claim 3 wherein positioning the nerve modulation device within a renal blood vessel further comprises positioning the nerve modulation device within a renal artery of the patient.

5. The method of claim 1 wherein positioning the nerve modulation device in a vicinity of post-ganglionic neural fibers comprises percutaneously advancing the nerve modulation device within a renal vasculature of the patient proximate to a renal nerve of the patient.

6. The method of claim 1 wherein reducing neural communication to and from the kidney with the nerve modulation device comprises thermally modulating afferent and efferent nerves via the nerve modulation device.

7. The method of claim 6 wherein thermally modulating the neural fibers comprises heating the afferent and efferent nerves.

8. The method of claim 7 wherein heating the afferent and efferent nerves comprises at least partially ablating a renal plexus of the patient.

9. The method of claim 7 wherein heating the afferent and efferent nerves comprises delivering RF energy to a renal plexus of the patient.

10. The method of claim 6 wherein thermally modulating the afferent and efferent nerves of the patient comprises cooling the afferent and efferent nerves.

11. The method of claim 10 wherein cooling the afferent and efferent nerves comprises reducing neural communication along the afferent and efferent nerves via cold ablation.

12. The method of claim 1 wherein reducing neural communication to and from the kidney with the nerve modulation device comprises electrically blocking afferent and efferent nerves proximate to the nerve modulation device with the nerve modulation device.

13. The method of claim 1 wherein reducing neural communication to and from the kidney with the nerve modulation device comprises delivering a neuromodulatory agent to afferent and efferent nerves proximate the nerve modulation device.

14. The method of claim 1 wherein reducing neural communication to and from the kidney with the nerve modulation device comprises blocking at least one of afferent and efferent neural activity along the neural fibers.

15. A method for treating a human patient with diagnosed congestive heart failure, the method comprising:

positioning a nerve modulation device in a vicinity of post-ganglionic neural fibers that innervate a kidney of the patient; and

reducing neural communication to and from the kidney with the nerve modulation device,

wherein reducing neural communication to and from the kidney significantly improves a measureable physiological parameter associated with the congestive heart failure of the patient.

16. A method for treating a human patient with diagnosed chronic renal failure, the method comprising:

positioning a nerve modulation device in a vicinity of post-ganglionic neural fibers that innervate a kidney of the patient; and

reducing neural communication to and from the kidney with the nerve modulation device,

wherein reducing neural communication to and from the kidney significantly improves a measureable physiological parameter associated with the chronic renal failure of the patient,

wherein the kidney continues to secrete renin in the patient after reducing neural communication with the nerve modulation device.

17. A method for treating a human patient with diagnosed acute myocardial infarction, the method comprising:

positioning a nerve modulation device in a vicinity of post-ganglionic neural fibers that innervate a kidney of the patient; and

reducing neural communication to and from the kidney with the nerve modulation device,

wherein reducing neural communication to and from the kidney significantly improves a measureable physiological parameter associated with the acute myocardial infarction of the patient.

18. A method for treatment of a human patient via renal denervation, the method comprising:

positioning a renal denervation catheter having a treatment device in a vicinity of post-ganglionic neural fibers that innervate a kidney of the patient; and

reducing neural communication to and from the kidney with the treatment device,

wherein reducing neural communication to and from the kidney results in a therapeutically beneficial reduction in blood pressure of the patient.

19. The method of claim 18 wherein positioning the renal denervation catheter in a vicinity of post-ganglionic neural fibers comprises positioning the renal denervation catheter within a renal artery of the patient.

20. The method of claim 18 wherein reducing neural communication to and from the kidney with the treatment device comprises delivering RF energy to the neural fibers.

21. The method of claim 18 wherein reducing neural communication to and from the kidney with the treatment device comprises delivering a neuromodulatory agent to the neural fibers.

22. The method of claim 18 wherein reducing neural communication to and from the kidney with the treatment device comprises reducing neural communication via cold ablation.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2013
From: MEDTRONIC ARDIAN LLC
To: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
Reel/Frame 030285/0723 →
CHANGE OF NAME Recorded Apr 25, 2013
From: ARDIAN, INC.
To: MEDTRONIC ARDIAN LLC
Reel/Frame 030293/0781 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2006
From: DEMARAIS, DENISE; GIFFORD, III, HANSON; DEEM, MARK; SUTTON, DOUGLAS; LEVIN, HOWARD R.; GELFAND, MARK
To: ARDIAN, INC.
Reel/Frame 017935/0333 →
Continuity (18)
Continuation In Part 10408665 · Apr 8, 2003
Continuation In Part 11133925 · May 20, 2005
Continuation 10900199 · Jul 28, 2004
Continuation In Part 10408665
Continuation In Part 11368553
Continuation In Part 11189563 · Jul 25, 2005
Continuation In Part 11129765 · May 13, 2005
Continuation In Part 11266993 · Nov 4, 2005
Continuation In Part 11363867 · Feb 27, 2006
Continuation In Part 11189563
Continuation In Part 11266993
Provisional Application 60442970 · Jan 29, 2003
Provisional Application 60415575 · Oct 3, 2002
Provisional Application 60370190 · Apr 8, 2002
Provisional Application 60616254 · Oct 5, 2004
Provisional Application 60624793 · Nov 2, 2004
Provisional Application 60813589 · Dec 29, 2005
Related Publication 20060212078A1 · Sep 21, 2006